Innova Biosciences Ltd (Cambridge, UK), a leader in the field of bioconjugation, has been awarded €455,000 of a €3,000,000 European grant. Through the PROACTIVE consortium along with Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University, and Integromics S.L., a unique high throughput plasma screening platform will be developed for the discovery of biomarkers of early stage cancer.
Innova Biosciences has had enormous success with its range of Lightning-Link™ bioconjugation products, which provide a uniquely simple method for joining biomolecules, a process carried out in thousands of research laboratories worldwide. Innova Biosciences’ participation in the PROACTIVE consortium to develop immunodiagnostics reagents will help cement the company’s position as a world leader in bioconjugation technology.
Commenting on the EU grant Dr Nick Gee, CEO of Innova Biosciences said “We are delighted to be granted such a prestigious award which recognises Innova’s proprietary knowledge and expertise. Participating in the development of a new immunodiagnostic platform that will facilitate early stage cancer detection is an exciting application of our technology, which will directly benefit human health.”
About the company: Innova Biosciences is a growing, dynamic business, based in Cambridge, UK. At the core of Innova’s business is the Lightning-Link™, an innovative technology that simplifies production of bioconjugates for use in R&D applications, drug discovery and diagnostics. The expanding Lightning-Link™ portfolio currently consists of 43 products and is sold to research laboratories in over 30 countries around the world.
